Editor in Chief Dr KK Aggarwal, Padma Shri Awardee                                                                               Dated:24 December,2019

FDA approves first generic of Bristol-Myers, Pfizer's blood thinner Eliquis

The approval was granted to Micro Labs Ltd and Mylan Pharmaceuticals Inc, the agency said.

The U.S. Food and Drug Administration said on Monday it has approved the first generic version of Bristol-Myers Squibb Co and Pfizer Inc's blood thinner Eliquis.

The approval was granted to Micro Labs Ltd and Mylan Pharmaceuticals Inc, the agency said.

Sales of Eliquis, which Bristol-Myers co-developed with Pfizer, rose 22% to $1.93 billion and made up about 30% of the Bristol-Myers' total revenues in the latest reported quarter. ....read more


Minimizing Hypoglycemia in Diabetes

The US Department of Health and Human Services has identified hypoglycemia as one of the top three preventable and measurable adverse drug events in a recent article published in the December 11 issue of the Journal of Clinical Endocrinology and Metabolism.

Hypoglycemia is defined in

Level 1: Glucose < 70 mg/dL and = 54 mg/dL

Level 2: Glucose < 54 mg/dL; needs immediate action. ....read more


Why do We Worship the Tulsi Plant?

Yanmule sarvatirhaani

Yannagre sarvadevataa

Yanmadhye sarvavedaascha ....read more


In 2020 I would like the new healthy policy to


Most Popular Videos

Wheat Disorders with Ishi Khosla


Medbytes

       


Healthcare News Monitor

CNBCTV18- PTI

Drug major Glenmark Pharmaceuticals has inked a licensing pact with Mankind Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country. Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm. "This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment," Mankind Pharma Director of Marketing Sanjay Koul said in a statement. Remogliflozin is economical than other similar agents currently available in sodium glucose co-transporter-2 (SGLT2) inhibitors class, which shall help for its better access among middle and low socio-economic strata of the society, he added. In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials. Subsequently, the company launched the drug under the brand names 'Remo' and 'Remozen'. "Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management," Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said.

Entrackr- Gaurav Tyagi

Selling medicines online has been a great challenge as this space witnessed regulatory challenges time and again in 2019. While the Delhi High Court had ordered all state governments to ban the online sale of medicines in January this year, the central drug regulator had asked states to enforce a court directive prohibiting online medicine sales this month. Amidst this regulatory uncertainty, Gurugram-based 1mg has demonstrated decent growth with a 2.8X jump in operating revenue. Registering 180% growth, it has posted total operating revenue of Rs 240.85 crore. The company collected Rs 39.45 crore from offering marketplace services while Rs 68.3 crore through online diagnostics and lab testing services in year ending March 2019. It also made Rs 67.8 lakh from collection charges. Importantly, the overall revenue from services grew 90.2% from Rs 41.8 crore in FY18 to Rs 79.5 crore in FY19. All services together accounted for a little over one-third of the total revenues generated by 1mg during last fiscal.

The Times of India- Rupak Banerjee

HOWRAH: A Howrah-based gynaecologist was abducted near Amta station on Monday and the four bike-borne armed kidnappers demanded Rs 20 lakh as ransom. The victim, Kalyan Kumar Dey, was later rescued with the help of locals from his own neighbourhood on Howrah’s Ramcharan Sett Road. Two of the abductors were arrested while search is on for the other two. Dey, who lives on one floor of a building that houses his nursing home, had gone to his chamber near Amta station when he was abducted. The doctor was driving his car when the men stopped him. They pulled him from the vehicle and dragged him into a narrow lane off Amta Station Road. There, they bargained for ransom. The four men initially demanded Rs 50 lakh. When Dey pleaded with them, they agreed to reduce the ransom to Rs 20 lakh. . Dey was asked to inform his family to hand over the money to two of the gang members — Jeet Gore and Suman Das. When the duo went to collect the money, locals intercepted and took them to the local Chatterjeehat police station where they admitted to the crime. Police traced the doctor’s location from information supplied by the two.

Mumbai Mirror- Vinay Dalvi

According to the officials of Mahatma Phule police station in Kalyan, Nauman Qazi, a resident of Mohane in Kalyan, had taken his three-month-old son Shahzeen to Shreedevi Hospital in Kalyan West on Monday morning following breathing troubles, fever, chest congestion and cough. “We had taken him to the hospital for nebulisation. They advised us to come in the afternoon and admit Shahzeen, claiming that he was suffering from a bad cough and would need frequent nebuliser treatment. They also gave him some syrup, which they are now claiming was Meftal P,” said Sabuddhin Qazi, a relative of the infant. Sabuddhin Qazi said as the family members came out of the hospital, they found the boy had stopped breathing. “When we checked with the doctor, he told us that he had died. Initially, the doctor, who is a trainee, accepted his mistake. Even the senior doctors told us that they had suspended him,” said Sabuddhin Qazi. The child was brought to us with lung blockages and at least a week-old fever. No hospital had admitted the child in Mohane, so they finally came to us. We only gave him Meftal P, and asked them to admit him. They refused to do so. They even gave us in writing that they did not want to admit the child,” said Balakrishna Shetty, chairman and managing director of Shreedevi Hospital. Shetty claimed that theirs was the only hospital in the area, which has 24-hour MD Medicine and MD Anaesthesia on the campus. “So, how can the child be treated by a trainee?” he said. Both the parties have approached the police with their complaints. “We are waiting for the postmortem report to ascertain the cause of death and investigate any negligence on the part of the hospital. The hospital authorities have also lodged a complaint against the family for slapping the doctor and abusing him.